This is a randomized, double-blind, controlled and multi-center Phase III clinical trial to evaluate the safety and efficacy of ASC40 tablets combined with bevacizumab in the treatment of adult patients with recurrent glioblastoma. After standard radiotherapy and chemotherapy (temozolomide), the subject first experienced clinical recurrence or progression.
|Treatment||bevacizumab, Placebo Tablets, ASC40 tablets|
|Clinical Study Identifier||NCT05118776|
|Sponsor||Ascletis Pharmaceuticals Co., Ltd.|
|Last Modified on||10 July 2022|
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
No annotations made yet
Congrats! You have your own personal workspace now.